PARIS — New results from a large prospective trial give a better idea of how a blood test that can detect multiple cancers performs in a "real-life" setting. "As this technology develops, people must ...

Please provide your email address to receive an email when new articles are posted on . The rate of non-CRC malignancies at 1 year was 0.8% in the false-positive group and 0.9% in the true-negative ...

False discovery rate (FDR) control has become an essential tool in the analysis of high-dimensional data, where thousands or millions of simultaneous hypotheses are tested. The aim is to limit the ...

A prospective cohort study led by Yang Shao, PhD, president and CEO of Geneseeq Technology Inc. and professor at Nanjing Medical University, Nanjing, published in Nature Medicine, on a blood test ...

Forbes contributors publish independent expert analyses and insights. Jesse Pines is an expert in healthcare innovation and wellness. This voice experience is generated by AI. Learn more. This voice ...